Abstract This article presents an evidence‐based approach to the patient with newly diagnosed Parkinson disease (PD). It includes a discussion of current understanding aetio‐pathogenesis PD and clinical features, both motor non‐motor, that assist clinician in making this diagnosis. An management early stage is discussed, including emerging evidence benefits physical exercise condition, issues c...

Emerging data suggest that type 1 diabetes is a more aggressive disease in children than in adults, with important differences in pathophysiology and clinical course. Therefore, the efficacy of disease-modifying therapies may be different in the two populations. Understanding the developmental and regulatory pathways for type 1 diabetes-modifying therapies in children will enable industry, acad...

The treatment of multiple sclerosis (MS) has changed over the last 20 years. All immunotherapeutic drugs target relapsing remitting MS (RRMS) and it still remains a medical challenge in MS to develop a treatment for progressive forms. The most common injectable disease-modifying therapies in RRMS include β-interferons 1a or 1b and glatiramer acetate. However, one of the major challenges of inje...